Literature DB >> 11595479

Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity.

Z Nagy1, A Nagy, O Karádi, M Figler, G Rumi, G Süto, A Vincze, A Pár, G Mózsik.   

Abstract

BACKGROUND: the developmental mechanism of inflammatory bowel disease (IBD) in patients is unknown, but it may be influenced by different environmental and genetical factors. AIMS of this study were: (1) to classify the IBD patients according the disease activity; and (2) to determine the presence of factor V Leiden mutation in IBD patients. PATIENTS AND METHODS: the observation was carried out in 49 patients with Crohn's disease (CD) and 29 patients with ulcerative colitis (UC). None of them had a history of thrombotic episodes. IBD was diagnosed by conventional clinical, endoscopic, radiological and histological criteria. The factor V Leiden mutation was detected by the polymerase chain reaction (PCR) method. Crohn's disease activity index (CDAI) was evaluated using the method of the National Cooperative Crohn's Disease Study. We determined the UC disease activity according to Truelove-Witts classification.
RESULTS: The prevalence of factor V Leiden mutation was increased in both populations of the patients to compare it with healthy persons (14.28 and 27.58% vs. 5.26%, n=7/49 and 8/29 vs. 3/57). The statistical analysis did not show a significant relationship between the CDAI or the Truelove-Witts grade in UC and the presence of Leiden mutation.
CONCLUSION: the presence of factor V Leiden mutation probably has a role in the development of IBD. Our results suggest a higher prevalence of this mutation in Central European patients than in Southern, Northern Europe or America, may be due to the genetical differences of these populations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595479     DOI: 10.1016/s0928-4257(01)00067-5

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  5 in total

1.  Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary.

Authors:  Gyula Mózsik; György Rumi; András Dömötör; Mária Figler; Beáta Gasztonyi; Elod Papp; Alajos Pár; Gabriella Pár; József Belágyi; Zoltán Matus; Béla Melegh
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease?

Authors:  Emma Attvall; Attila Frigyesi; Berit Sternby
Journal:  Int J Colorectal Dis       Date:  2006-01-13       Impact factor: 2.571

Review 3.  Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Jie Liang; Shengjun Wu; Bin Feng; Shaoni Lei; Guanhong Luo; Jingbo Wang; Kai Li; Xiaohua Li; Huahong Xie; Dexin Zhang; Xin Wang; Kaichun Wu; Danmin Miao; Daiming Fan
Journal:  J Gastroenterol       Date:  2011-07-30       Impact factor: 7.527

Review 4.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

5.  Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study.

Authors:  Laszlo Lakatos; Tunde Pandur; Gyula David; Zsuzsanna Balogh; Pal Kuronya; Arpad Tollas; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.